Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna,

Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on
 Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013

PR Newswire

JERUSALEM, April 18, 2013

JERUSALEM, April 18, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
developer of oral delivery systems, announced today that its abstract, titled
"Oral insulin may be effective in lowering hepatic insulin resistance and
inflammation in patients with type 2 diabetes," has been selected for poster
presentation at the 5th International Congress on Prediabetes and the
Metabolic Syndrome in Vienna, Austria. The poster will be presented by Dr.
Ehud Arbit, Oramed's Director of Research & Development on Friday, April
19^th, during poster session #1: "Insulin Resistance: Various Aspects." 

The 5^th Congress on Prediabetes and the Metabolic Syndrome will be addressing
the markedly increased risk of diabetes and cardiovascular disease by
exploring the latest issues and presenting pioneering research from world
leaders and specialists in the field.

For more information on the Congress please visit their website, here.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
approaching Phase 2 clinical trials under U.S. IND, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a
trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com.

The company's fact sheet,the content of which is not part of this press
release, can be viewedhere.

Forward-looking statements: This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss our oral insulin and oral exenatide candidates approaching Phase 2
clinical trials under U.S. IND and 2a clinical trials, respectively. These
forward-looking statements are based on the current expectations of the
management of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product candidates;
competition from other pharmaceutical or biotechnology companies; and our
ability to obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the following
factors, among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in technology and
market requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our technology
as we progress further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally good results
in real settings; our patents may not be sufficient; and final that products
may harm recipients, all of which could cause the actual results or
performance of Oramed to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Oramed
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office:+972-2-566-0001
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.
 
Press spacebar to pause and continue. Press esc to stop.